Please use this identifier to cite or link to this item:
|Title:||Recent progress and clinical importance on pharmacogenetics in cancer therapy||Authors:||Soh, T.I.P.
|Issue Date:||1-Oct-2011||Citation:||Soh, T.I.P., Yong, W.P., Innocenti, F. (2011-10-01). Recent progress and clinical importance on pharmacogenetics in cancer therapy. Clinical Chemistry and Laboratory Medicine 49 (10) : 1621-1632. ScholarBank@NUS Repository. https://doi.org/10.1515/CCLM.2011.715||Abstract:||Recent advances have provided unprecedented opportunities to identify prognostic and predictive markers of efficacy of cancer therapy. Genetic markers can be used to exclude patients who will not benefit from therapy, exclude patients at high risk of severe toxicity and adjust dosing. Genomic approaches for marker discovery now include genome-wide association studies and tumor DNA sequencing. The challenge is now to select markers for which there is enough evidence to transition them to the clinic. The hurdles include the inherent low frequency of many of these markers, the lengthy validation process through trials, as well as legislative and economic hurdles. Attempts to answer questions about certain markers more quickly have led to an increased popularity of trials with enrichment design, especially in light of the dramatic phase I results seen in recent months. Personalized medicine in oncology is a step closer to reality. © 2011 by Walter de Gruyter Berlin Boston.||Source Title:||Clinical Chemistry and Laboratory Medicine||URI:||http://scholarbank.nus.edu.sg/handle/10635/115547||ISSN:||14346621||DOI:||10.1515/CCLM.2011.715|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jul 12, 2019
WEB OF SCIENCETM
checked on Jul 5, 2019
checked on May 25, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.